Research progress of nanovaccine in anti-tumor immunotherapy

Tumor vaccines aim to activate dormant or unresponsive tumor-specific T lymphocytes by using tumor-specific or tumor-associated antigens, thus enhancing the body’s natural defense against cancer. However, the effectiveness of tumor vaccines is limited by the presence of tumor heterogeneity, low immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Min, Liu, Xiyu, Qian, Zhangbo, Fan, Dianfa, Sun, Xinjun, Zhong, Liping, Wu, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484753/
https://www.ncbi.nlm.nih.gov/pubmed/37692854
http://dx.doi.org/10.3389/fonc.2023.1211262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484753/
https://www.ncbi.nlm.nih.gov/pubmed/37692854
http://dx.doi.org/10.3389/fonc.2023.1211262

Ejemplares similares